Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OFIX vs LDRH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OFIX Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 6–2 Matrix Metrics)

OFIX Overall Winner 6-Pillar Tally: OFIX 5 – 0 LDRH (1 Tie) Matrix Metrics: OFIX 6 – 2 LDRH

As of Nov 20, 2026, Orthofix Medical Inc. (OFIX) is the stronger overall head-to-head candidate over LDRH (LDRH) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OFIX carries a Unified Composite Score of 47.8/100 (HOLD) at $6.07 (N/M Forward P/E, -2.1% operating margin), whereas LDRH carries 41.1/100 (SELL) at $23.79 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: OFIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.7); meanwhile LDRH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OFIX vs LDRH
OFIX NASDAQ Head-to-Head Winner
Orthofix Medical Inc. Common Stock (DE)
Surgical & Medical Instruments & Apparatus
$6.07
-4.26% 1D
Market Cap $258.4M
TTM Revenue $835M
Forward P/E N/M
Beta / 30D Vol 1.05β · 83% Vol
Unified Composite Score
47.8 / 100 HOLD
Tech 45.0 Fund 50.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.5%), weak momentum, RSI 26
RSI-14: 25.7 · SMA20: $8.08 · SMA50: $8.82
LDRH US Equity
LDRH
Institutional Equity
$23.79
-0.21% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.10β · 3% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 32.0 Fund 47.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 29
RSI-14: 29.0 · SMA20: $23.95 · SMA50: $24.03

6-Pillar Scorecard Institutional Category Breakdown (OFIX 5 – 0 LDRH)

Columns: Metric · OFIX · LDRH
1. Valuation Multiples OFIX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x N/M
2. Growth & Scale OFIX
Revenue Growth (YoY) +1.1% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $835M N/A
Market Cap $258.4M N/A
3. Profitability & Quality OFIX
Gross Margin 70.8% N/A
Operating Margin -2.1% N/A
Net Profit Margin -5.4% N/A
Return on Equity (ROE) -10.3% N/A
4. Balance Sheet & Cash Flow OFIX
Cash Generation (TTM) $41M EBITDA N/A
Cash Flow Margin 4.9% EBITDA Mgn N/A
Net Cash / Leverage $10.54 Book/Sh · -10.3% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 40.1% (3rd %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat OFIX
OpEx & R&D Intensity 72.9% of Rev ($609M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OFIX (6) vs LDRH (2)
Institutional Metric OFIX LDRH Criterion Row Edge
Market Capitalization
Scale
$258.4M N/A Larger Scale OFIX
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1.1% N/A Higher Growth OFIX
Operating Margin (TTM)
Profitability
-2.1% N/A Higher Margin OFIX
Net Profit Margin
Profitability
-5.4% N/A Higher Margin OFIX
Return on Equity (ROE)
Capital Efficiency
-10.3% N/A Higher ROE OFIX
52-Week Range Position
Momentum
0% ($6–$16) 1% ($24–$25) Stronger Trend LDRH
Beta / 30D Volatility
Risk Regime
1.05β · 83% Vol 0.10β · 3% Vol Lower Realized Risk LDRH
Unified Institutional Score
Composite Signal
47.8 / 100 (HOLD) 41.1 / 100 (SELL) Higher Composite OFIX
Trailing 12M Revenue (USD)
Operating Scale
$835M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
70.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$41M EBITDA ($10.54 Book/Sh · -10.3% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LDRH +38.47 pp
OFIX: -39.24% · LDRH: -0.77%
3M Horizon LDRH +34.9 pp
OFIX: -38.0% · LDRH: -3.1%
6M Horizon LDRH +39.93 pp
OFIX: -43.53% · LDRH: -3.6%
1Y Horizon LDRH +53.79 pp
OFIX: -58.02% · LDRH: -4.23%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OFIX vs LDRH. Trailing 12-month operating profitability (OFIX -2.1% vs LDRH N/A) and valuation multiples (OFIX N/M vs LDRH N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OFIX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$835M
Gross Margin70.8%
Op. Margin-2.1%
ROE / Fwd P/E-10.3% · N/M
LDRH ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OFIX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 40.1%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OFIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LDRH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LDRH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OFIX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $258.4M market capitalization and -2.1% operating margin.
OpEx & R&D Reinvestment 72.9% of Rev ($609M)
90D Engineering Disclosures 0 Published
LDRH Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OFIX vs LDRH Key Questions & Quantitative Answers

As of Nov 20, 2026, Orthofix Medical Inc. (OFIX) is the stronger overall head-to-head candidate over LDRH (LDRH) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OFIX carries a Unified Composite Score of 47.8/100 (HOLD) at $6.07 (N/M Forward P/E, -2.1% operating margin), whereas LDRH carries 41.1/100 (SELL) at $23.79 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: OFIX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 25.7); meanwhile LDRH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 29.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OFIX leads the Growth & Scale pillar: OFIX posts +1.1% YoY revenue growth and +0.0% YoY earnings growth on $835M TTM revenue (70.8% gross margin, -2.1% operating margin), compared with LDRH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, OFIX generates $835M in USD-normalized revenue versus N/A for LDRH. In operating R&D and SG&A reinvestment, OFIX deploys 72.9% of Rev ($609M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LDRH.

OFIX screens cheaper on headline valuation multiples. OFIX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (4.9% EBITDA margin), whereas LDRH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OFIX (-10.3% ROE) versus LDRH (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, OFIX carries 40.1% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.05β · 83% Vol realized risk). By comparison, LDRH carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.10β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.